A new approach to eliminate breast cancer using a specific protein inhibitor.
A novel therapeutic strategy to eradicate breast cancer through Hsp90 inhibition and reduced immune tolerance
['FUNDING_R01'] · AUGUSTA UNIVERSITY · NIH-11044183
This study is exploring a new treatment that uses a special peptide to help your immune system better fight breast cancer, especially for those who haven't had success with current therapies, and it aims to make the treatment safer and more effective.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | AUGUSTA UNIVERSITY (nih funded) |
| Locations | 1 site (AUGUSTA, UNITED STATES) |
| Trial ID | NIH-11044183 on ClinicalTrials.gov |
What this research studies
This research investigates a novel therapeutic strategy that targets heat shock protein 90 (Hsp90) to enhance the immune system's ability to fight breast cancer. The approach involves using a cyclic peptide called EnnA, which has shown promise in promoting immune cell infiltration into tumors and inducing cancer cell death without triggering harmful side effects. By combining this treatment with existing immunotherapies, the goal is to improve outcomes for patients who currently do not respond to standard immune checkpoint blockade therapies. Patients may benefit from a more effective treatment option that harnesses their own immune system to combat cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with breast cancer who have not responded to traditional immunotherapy treatments.
Not a fit: Patients with non-breast cancer diagnoses or those who have already responded well to existing immunotherapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for breast cancer patients, potentially leading to better survival rates and improved quality of life.
How similar studies have performed: Other research has shown promising results with similar immunotherapy approaches, indicating potential for success in this novel strategy.
Where this research is happening
AUGUSTA, UNITED STATES
- AUGUSTA UNIVERSITY — AUGUSTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHADLI, AHMED — AUGUSTA UNIVERSITY
- Study coordinator: CHADLI, AHMED
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy